REVIEWS  LATEST DEVELOPMENTS IN SFA MANAGEMENT 

The Journal of Cardiovascular Surgery 2014 August;55(4):477-81

Copyright © 2014 EDIZIONI MINERVA MEDICA

language: English

Which is currently the best strategy for treatment of SFA in-stent restenosis?

Elens M. ¹, Verbist J. ¹, Keirse K. ², Van Den Eynde W. ¹, Peeters P. ¹ ✉

¹ Department of Cardiovascular and Thoracic Surgery, Imelda Hospital, Bonheiden, Belgium; ² Department of Vascular Surgery, Regionaal Ziekenhuis Tienen, Tienen, Belgium

Stents have been created to prevent vessel recoil after percutaneous transluminal angioplasty (PTA). Despite the evolution in stent design, intimal hyperplasia and stent fractures and the resulting in-stent restenosis (ISR) still occur. Different strategies to treat ISR have been described with variable results in patency rates in the short and the long-term. PTA only in the treatment of ISR showed high procedural success, but the mid and long-term patency rates were very disappointing. Atherectomy devices have showed same insufficient results. If stent fracture is the cause of the ISR, the fracture has to be overstent. The best two options are covered stents and drug eluting stents (DES). Drug eluting devices like DES and drug eluting balloons (DEBs) showed promising results, with patency rates up to over 90% after one year. DEBs have the advantage of leaving nothing behind. Combined treatment of ISR with atherectomy and DEB has a similar good result. Endovascular brachytherapy showed high patency rates after one year but this technique is limited due to the time-consuming nature of the procedure, complex radiation safety measurements, and staffing requirements. Overall drug-eluting devices are emerging as the best treatment of SFA ISR with patency rates over 90% after 2 years.